Hematopoietic progenitor cell transplantation is often associated with severe mucosal toxicity. The need for parenteral analgesics and parenteral nutrition are evidence of the severity of the problem in individual patients. However, the increased risk for systemic infection related to bacteremia associated with the breakdown of mucosal barriers is a significant cause of morbidity and mortality as well. There is a multitude of grading scales, demonstrating the lack of consensus among clinicians in this area. Multiple agents have been used prophylactically and therapeutically to address mucositis. While efforts have been less successful in the past, the advent of newer agents including amifostine, keratinocyte growth factor, transforming growth factor beta and interleukin-11 provides hope that this toxicity will be significantly decreased in the near future.
keratinocyte growth factor; transforming growth factor beta Hematopoietic progenitor cell transplantation (HPCT) is commonly associated with significant morbidity from injury to the gastrointestinal mucosa. 1 Oral mucositis usually occurs between 2 and 18 days following HPCT. 2 The high turnover rate of mucosal epithelial cells renders this tissue highly vulnerable to direct toxic injury from chemotherapy and radiation. Damaged mucosa leads to significant morbidity and impaired quality of life related to oral mucositis and diarrhea. Additionally, derangements in immune mechanisms, including secretion of toxic cytokines and prolonged neutropenia contribute to the severity of tissue damage and duration of mucositis. While severe oral pain is often the most obvious and troublesome symptom to patients undergoing HPCT, gastrointestinal toxicity is also associated with more life-threatening morbidity and mortality. 3 Prolonged narcotic use may lead to significant problems, including ileus and possibly addiction in the long term. Gastrointestinal toxicity has also been associated with a delay in neutrophil recovery 3 and a longer duration of parenteral nutritional support.
Each preparative regimen used in HPCT is associated with its own specific side effects. Patients develop varying levels of mucosal injury based on the choice of preparative regimen; however, all myeloablative preparatory regimens are associated with some degree of mucosal toxicity. 2 It is telling that grade III-IV mucositis has become a very common side effect in the HPCT field to the extent that 90-100% of patients in some recent studies develop this problem with the associated need for parenteral nutrition and parenteral analgesia, and regimens may still be considered 'well tolerated'. 4, 5 Unfortunately, progress in developing newer agents has been hampered by the lack of good preclinical models. While there are murine and hamster models of mucosal toxicity and multiple animal models of allogeneic HPCT, none are truly valid models of the mucosal toxicity usually associated with HPCT. Thus, our understanding of the pathophysiology of the problem, and attempts at alleviating it have been hampered. There appear to be two major events leading to symptomatic mucositis in HPCT patients. 6 The first is direct mucosal injury, which can be related to toxic injury from chemotherapy, or radiation therapy or to local infections. This is exacerbated by the cytopenias associated with HPCT. While clinical evidence of injury is usually not seen until 3-4 days after the onset of the preparative regimen, the actual damage starts at the time the first stomatoxic agent is given. Many different agents are known to cause injury and the most commonly by used in HPCT are listed in Table 1 . These include chemotherapy and radiation used in the preparative regimens and methotrexate that is commonly used for GVHD prophylaxis. Each agent individually may predispose to mucosal injury. Combination therapy, while adding to the effectiveness of the preparative regimens also adds to the toxicity.
Following disruption of the basal cell layer of the mucosal epithelium, local cytokines are released 7 including interleukin-1 and tumor necrosis factor alpha (TNF-a), leading to futher damage. Following direct injury, a second phase has been described 6 during which aerobic and anaerobic bacteria cause local infections and may lead to systemic infection in up to 75% of HPCT patients. This phase is complicated by the development of neutropenia and the use of systemic broad spectrum antibiotics (which may lead to the development of resistant organisms). An increased risk of bacterial infections has been associated with more severe mucositis in several studies. 3, 8 In a study of 202 patients, Rapoport et al 3 found that mucositis was significantly more severe in recipients of marrow grafts compared with peripheral blood stem cell grafts, in recipients of unrelated donor or matched sibling graft compared with autologous grafts or who carried a diagnosis of acute leukemia or myelodysplasia. Similar results were obtained when the duration of parenteral nutrition support was used as the measure of gastrointestinal toxicity, but prolonged neutropenia also contributed when this analysis was used. In this study, higher peak mucositis scores and prolonged use of parenteral nutrition both correlated with the occurrence of bacteremias and transplant-related mortality. While 60% of patients with moderate to severe mucositis developed positive blood cultures, only 30% of patients with less severe mucositis developed this complication. Alpha hemolytic streptococcal infections in this setting are related to mucosal injury, particularly oral mucositis, and can be problematic. 9 Neutropenic enterocolitis and associated enteric Gramnegative infections are likewise related to mucosal injury in the lower gastrointestinal tract, and represent a significant cause of morbidity and mortality in the post-transplant setting. 10 The combination of infectious complications and pain with the consequent need for antibiotics, other supportive care for sepsis, parenteral narcotics, and parenteral nutrition result in increased length of hospital stay and increased cost. 1 In his recent report 'Oral Health in America', 11 the US Surgeon General commented on oral mucositis as a doselimiting side effect of several anticancer agents, including 5-fluorouracil, methotrexate and doxorubicin. Radiation, including both radiation delivered for patients with head and neck malignancies and total body irradiation associated with HPCT, may be associated with systemic complications, particularly in patients with periodontal disease. While ulceration of gingival epithelium may not be directly observed, it represents a source for disseminated infections by a variety of organisms, as discussed above. Viral infections, particularly those in the herpes family, and fungal superinfection may further complicate the picture and lead to increased morbidity and mortality.
Mucosal toxicity grading scales
Discussions about mucosal injury are hampered by a lack of consistency among investigators when describing toxicity. Grading scales vary among institutions. The most commonly used is that of the World Health Organization 12 (see Table 2 ), which is similar to that of the National Cancer Institute and the cooperative oncology groups (ECOG, SWOG, CALGB). 13, 14 These scales are simple and easily applied, but variability among graders is common. Other grading systems, including the Oral Mucosal Assessment Scale 15 and the University of Nebraska Oral Assessment Scale 16 are more detailed and may be more reproducible. In the late 1980s, 17,18 a grading system specific for patients undergoing bone marrow transplantation was published. Commonly known as the 'Bearman Criteria,' it provides a grading scale from 1 to 3 for all major organs, including the oral mucosa, which may be affected following HPCT. While the Bearman criteria have limitations, they have held up well in HPCT studies. More recently, 15 a newer scoring system -the Oral Mucosal Assessment Score -was developed and validated in a largescale study. A panel of experts including nurses, dental hygienists, physicians and dentists agreed on a grading scheme based on a consensus of mucositis indicators. Indicators were either primary (ulceration, pseudomembrane formation, erythema in specific sites within the mouth) or secondary (oral pain, swallowing and the ability to eat as assessed by the patient). It has been validated in several large-scale studies with high interobserver consistency and scores that demonstrated good correlation with symptoms. It is, however, more cumbersome and time consuming for the clinician who scores the mucosal pathology. The University of Nebraska Oral Assessment Score 16 takes into consideration not only the appearance of the oral mucosa and swallowing function, but also voice 19 Unfortunately, the multitude of grading scales, although attempting to provide for uniformity, often provide confusion in interpreting the toxicities associated with a particular therapy. Grade 0 is understood as 'normal' to all investigators. However, the severity of grade 2 or 3 toxicity is quite variable from one scoring system to the next. As reflected in the multiplicity of grading schemes, no single system has emerged which is consistently applied in clinical trials.
Thus, the need for prevention or early intervention is obvious. As noted above, 11 the Surgeon General has made oral health a priority. He has included patients receiving chemotherapy and those undergoing HPCT. As investigators learn more about the pathophysiology of mucosal damage in this setting, newer approaches and agents will be developed. These are described in further detail below and in Table 3 , and include both attempts at prophylaxis and treatment. In addition, efforts must be made to understand each individual patient's risk prior to undergo high-dose therapy. It has been recommended that all patients undergo a pretransplant oral examination by a qualified dentist prior to embarking on this course. 20 
Oral cryotherapy
Decreasing blood flow to oral mucosa should also serve to decrease mucosa exposure to the drug. Therefore, it is assumed that oral cryotherapy will, through vasoconstriction, decrease the toxicity of agents associated with mucosal damage. When used with agents with short halflives, such as 5-fluoruracil (5-FU) and melphalan, this should be particularly efficacious. This has been studied most consistently with 5-FU, but could be applied more broadly. Mahood et al 21 randomized 95 patients to receive a short course of cryotherapy during 5-FU and leucovorin therapy. Patients who were randomized to receive therapy were asked to suck on ice chips for 30 min, starting 5 min prior to a 5-FU infusion. During a second cycle of 5-FU and leucovorin, patients who had previously received no therapy were asked to use cryotherapy, whereas those who 
Chlorhexidine
Chlorhexidine is a broad-spectrum topical antimicrobial that has been effective in preventing gingivitis and oral infection. Mouth rinses with chlorhexidine have been used in many transplant centers as part of 'standard of care' for many years. However, in a randomized study of 100 patients, 24 chlorhexidine use resulted in a trend towards improved oral hygiene and oral candidiasis, but there was no distinct therapeutic advantage of chlorhexidine over placebo in reducing mucositis, oral pain, or oral (re) infection with herpes simplex virus.
Oral decontamination
Other attempts have been made at oral decontamination both in patients undergoing HPCT and those undergoing other therapies with a high incidence of mucositis. For example, Symonds et al 25 studied 275 patients undergoing radiation therapy for head and neck malignancies. Patients were randomized to receive an antibiotic pastille (polymyxin E 2 mg, tobramycin 1.8 mg, and amphotericin B 10 mg) or placebo four times a day from the start of radiation through the resolution of radiation induced symptoms. There was a beneficial effect for patients receiving the antibiotic pastilles in terms of functional consequences of mucosal injury, including dysphagia and weight loss. There was also a striking decrease in the number of oral yeast infections, but no difference in the oral carriage of Gram-negative rods. A similar study, by Okumo et al, 26 also looked at the use of these pastilles in comparison to chlorhexidine or placebo mouth rinses. Patients who were receiving radiation therapy that involved at least one-third of the oral cavity were randomized to receive one of the three therapies four times daily. The arms of the study that included chlorhexidine and placebo mouth rinses were closed early when the chlorhexidine was found to be detrimental. The study continued with a randomization between a placebo lozenge and the antibiotic lozenge. There were no difference in the mucositis scores or in the incidence or duration of radiation therapy interruptions. Patients may have found some relief in symptoms, but there was no significant difference to warrant recommending use of the pastilles in this patient group. Given the decrease in dysphagia and oral yeast infections described by Symonds, 25 it is possible that patients at particularly high risk for theses complications, including HPCT recipients receiving radiation therapy or particularly stomatoxic therapy, may benefit. Further studies in this patient group are warranted.
Several different rinses have been used to prevent or treat mucosal injury. These are frequently favorite remedies of the treating clinician, rather than products which have undergone vigorous testing. Often they are remedies passed on from patient to patient. Recently, Dodd et al 27 looked at three of the more commonly used regimens in a randomized clinical trial. Adult patients undergoing 'stomatoxic' therapy who developed mucositis were invited to participate in the study. Patients undergoing induction therapy for acute leukemia, HPCT or patients with acquired immune deficiency syndrome were excluded. All patients received instruction regarding good oral hygiene as part of the PRO-SELF Mouth Aware Program and all patients undertook 12 days of mouth rinses four times daily. Patients were randomized to one of three rinses: chlorhexidine gluconate mouthwash (0.12%), 'Magic Mouthwash' (viscous lidocaine -0.5%, 5 ml + diphenhydramine hydrochloride -0.0312%, 0.25 ml + aluminum hydroxide suspension 14.75 ml), or 'salt and soda' mouth wash (1 teaspoon of salt and 1 teaspoon of sodium bicarbonate per pint of water). There was no benefit provided by any of the three rinses beyond that provided by the use of a systematic oral hygiene program.
Glutamine
Multiple studies have been performed to assess the effects of oral or intravenous glutamine on chemotherapy induced mucositis. Glutamine is the most abundant amino acid in plasma and is reduced significantly in plasma and tissue during sepsis or nutritional depletion. Its role in maintaining gastrointestinal integrity has been described previously. 28 Both animal models and human trials have demonstrated an increased glutamine requirement during certain catabolic states. 29 While the intravenous formulation has provided little benefit, oral glutamine has been found to be effective in reducing bacteremia and mucositis associated with methotrexate administration. 30 Studies of low-dose oral glutamine (2 g amino acid/m 2 b.i.d) in patients receiving standard doses of anthracycline-based chemotherapy regimens have shown a decrease in both severity and duration of oral mucositis. 31 There has been a mixed response to glutamine supplementation in HPCT patients. While one study suggested decreased ulceration, pain and oral bleeding in patients who received oral glutamine, 32 these findings did not reach statistical significance. Other studies 33, 34 have not shown a consistent benefit. However, given the trends which have been noted, additional studies are ongoing, including combination therapy with glutamine and other agents. There have been at least 20 randomized controlled clinical trials of glutamine in parenteral nutrition in adults or children. Most indicate some benefit from supplemental glutamine. Adding supplemental glutamine to parenteral nutrition in recipients of HPCT has led to increased glutamine levels and improved nitrogen balance without any adverse side effects. It has been associated with improved number of circulating lymphocytes and attenuation of extracellular fluid. However, there have been mixed results in terms of effects on diarrhea and mucositis. Oral glutamine has generally not been beneficial. However, in one study, Anderson et al 35 did show improved survival on day 28 post-HPCT and significantly less mouth pain and narcotic use in patients who received oral glutamine. In general, the use of either oral or parenteral glutamine has not been shown to be detrimental. Patients receiving parenteral nutrition should have particular attention paid to glutamine supplementation and nitrogen balance. However, ongoing studies are needed to further clarify the specific role of glutamine therapy in recipients of HPCT.
Pentoxifylline
Several studies have examined the use of pentoxifylline for the prevention of not only mucosal injury, but also other transplant-related toxicities. Pentoxifylline is a xanthine derivative capable of downregulating TNF-a. In preclinical models, 36 it decreased the production of radiation-induced TNF-a and decreased endotoxin production. In an interesting study by Bianco et al, 37 pentoxifylline was given to patients undergoing HPCT in a dose escalation study (1200, 1600 and 2000 mg/day). A total of 26 patients underwent allogeneic HPCT and four underwent autologous HPCT. Out of 30 patients, 24 received preparative regimens that included total body irradiation and six received preparative regimens that included only chemotherapy. Patients who received pentoxifylline had less mucositis, less hepatic veno-occlusive disease, less renal insufficiency, required less parenteral nutrition and were less likely to develop Xgrade II graft-versus-host disease (GVHD). A larger prospective randomized study 36 was conducted in 140 patients who received 1600 mg of pentoxifylline daily (400 mg, four times per day) starting with the first day of the preparative regimen and continuing through 100 days following HPCT. A total of 89 patients received autologous grafts, while 51 received allogeneic grafts. In all 62% received preparative regimens that included total body irradiation, while 38% received only chemotherapy. Patients who received an allogeneic graft received methotrexate for GVHD prophylaxis on days 1, 3 and 6 following HPCT. While there were no adverse side effects attributable to the pentoxifylline, there was also no difference in mucositis, veno-occlusive disease, survival, hematologic toxicity, renal toxicity, or septicemia. Thus, while pentoxifylline offered some early promise, its use cannot be advocated outside of a clinical trial setting.
GM-CSF
GM-CSF (sargramostim) has been used in an attempt to reduce the severity and duration of mucositis. GM-CSF is known to stimulate migration and proliferation of endothelial cells and to promote keratinocyte growth. 38, 39 Preclinical data have shown that topical application of GM-CSF to wounds results in improved wound healing. [40] [41] [42] Results of trials with patients suffering from mucositis following high-dose chemotherapy have been mixed. Several trials have looked at the use of intravenous GM-CSF in this setting. Nemunaitis et al 43 reported on 109 patients who were randomized to receive either 250 mg/m 2 / day or placebo. He found that patients receiving GM-CSF were less likely to develop Grade III/IV mucositis (8 vs 29%; P ¼ 0.005); however, the overall incidence of mucositis was no different from one group to another. In a study comparing a dose of 125 mg/m 2 /day continuous intravenous infusion with no growth factor, Gordon et al 44 reported a shorter duration of mucositis in patients receiving GM-CSF (12.2 vs 20.3 days; P ¼ 0.02). However, this was only observed in patients who received a preparative regimen of thiotepa, etoposide and total body irradiation. There was no difference in the severity or duration of mucositis when patients received a preparative regimen of thiotepa, etoposide and cyclophosphamide. Conversely, both Legros et al 45 and Atkinson et al 46 reported no reduction in the severity or duration of mucositis when patients received GM-CSF.
Other investigators have studied the use of topical GM-CSF in gel formulations or mouthwashes. Studies using GM-CSF prophylactically have not shown any benefit. 47, 48 Therapeutic use of GM-CSF mouth washes, starting with first sign or symptom of mucositis, has shown both a reduced severity and a decreased duration of mucositis.
49,50

Sucralfate
In a double-blind randomized control of sucralfate for the prevention of mucositis in patients undergoing HPCT, 51 severe mucositis was less frequent in patients who received sucralfate (29%) than in those who did not (47%; P ¼ 0.07). Patients who received sucralfate were also less likely to develop diarrhea (25 vs 53%; P ¼ 0.005). Although sucralfate has been used extensively for esophagitis related to gastroesophageal reflux disease and has been given in an attempt to ameliorate the toxicities of radiotherapy and chemotherapy in patients undergoing standard dose therapy for head and neck cancers, it has not otherwise been studied extensively in the HPCT setting. Additional studies are needed to investigate this agent, particularly with combination therapy.
Keratinocyte growth factors (KGF)
KGF are members of the fibroblast growth factor family, which have been shown in preclinical models to protect animals from chemotherapy and radiation induced gastrointestinal damage. 52, 53 In a study performed recently in normal monkeys, 52 investigators administered repifermin (keratinocyte growth factor 2), either intravenously or subcutaneously daily. Epithelial hyperplasia was found in the buccal mucosa and dorsal tongue of all monkeys, and esophageal thickening was also noted. The frequency and degree of hyperplasia was dose-dependent, with monkeys receiving 200 mg/kg/day IV developing more hyperplasia than those who received lower doses. While there were no gastric changes seen, there was mucosal and goblet cell hyperplasia in the intestine. These changes were greatly reduced, or resolved following discontinuation of repifermin. In vitro studies of more than a dozen cell lines 54 have not shown any enhanced neoplastic transformation with repifermin. Similarly, subcutaneous injection of repifermin in tumor-bearing nude mice did not promote tumor growth. 40 In a phase I study conducted in patients with colorectal cancer, 55 patients received KGF by intravenous bolus on days 1-3 followed by 5-fluoruracil and leucovorin on days 4-8. All cohorts who had received doses of at least 10 mg/ kg/day had decreased grades II-IV mucositis. In a recent phase 2 study in the autologous HPCT setting, 56 91 patients were randomized to receive repifermin or placebo. Repifermin was administered intravenously for 14 days at doses ranging from 1 to 50 mg/kg. Preparative regimens were expected to provide at least a 50% incidence of grade III or IV mucositis. The Oral Mucosal Assessment Scale was used to grade mucositis. The overall incidence of grade III or IV mucositis was only 38%. Minimal side effects, including hyperamylasemia, fever, and infection, occurred in similar numbers in patients receiving repifermin or placebo.
KGF may also provide other benefits in the allogeneic HPCT setting. Delayed immune reconstitution following transplant and the associated infectious complications are a significant cause of morbidity and mortality. Preclinical work has shown KGF to provide protection from thymic epithelial cell injury, thereby allowing more rapid immune recovery. 57 Furthermore, in a murine GVHD model, KGF was administered from day 3 through day 7 and significantly reduced the mortality and severity of the GVHD. While GVHD was reduced, the graft-versusleukemia effect was not compromised in mice receiving lethal doses of leukemia cells, as evidenced by a prolonged leukemia-free survival. 58 
Iseganan
Iseganan is a novel Protegrin-derived antimicrobial peptide preparation (oral solution) which has been studied in patients undergoing high-dose therapy and HPCT. In a recent randomized double-blind, placebo-controlled phase 3 trial, 59 patients received myeloablative chemotherapy that was expected to cause at least grade II mucosal toxicity (National Cancer Institute -Common Toxicity Criteria). Patients were followed for the development of infections, hospitalizations, and death. These events were more common in patients with peak stomatitis grades of III or IV than in those with lesser grades of mucosal toxicity (47.4 vs 32.9%, P ¼ 0.0145). The Iseganan oral solution was found to reduce stomatitis severity, oral pain and swallowing dysfunction.
Immunol oral rinse
Triclosan is a compound which has demonstrated antimicrobial, anti-inflammatory, analgesic, and anticytotoxic properties through downregulation of PGE2 production induced by TNF-a and IL1b in preclinical models. It is used throughout the world for treatment of gingivitis. Immunol oral rinse is a formulation of triclosan in an oral rinse which has recently been studied in a multicenter, doubleblind randomized trial to prevent mucositis in patients undergoing HPCT. 60, 61 Patients were randomized to receive either Immunol or antibiotic containing vehicle rinses four times daily from the start of the preparative regimen until engraftment or healing of all ulcers. Patients who received preparative regimens containing melphalan, etoposide, busulfan or TBI were more likely to develop severe mucositis. However, in this group, erythema and/or ulceration developed in 90.24% of patients in the control arm compared with only 68.89% in the treatment arm. There was also a significant reduction in the duration of mucositis (5.18 vs 7.88 days, P ¼ 0.011).
Interleukin 11
Interleukin-11 (rhIL-11) has been used to treat thrombocytopenia in patients receiving chemotherapy. Several investigators 62, 63 have looked into the use of IL-11 in preclinical models and found it to decrease the severity, frequency and duration of mucositis and to inhibit the release of proinflammatory mediators, leading to decreased levels of tumor necrosis factor, interleukin 12 and interferon g. There are less data in humans at present. However, given that IL-11 has been shown to block Th1 differentiation, by inhibition of IL-12, it was studied in a phase I investigation in patients with psoriasis. 64 Patients received subcutaneous injections of IL-11 in a dose escalation study. Out of 12 patients, seven responded with decreased keratinocyte production and decreased cutaneous inflammation. In a recently reported study, 65 patients who received a preparative regimen of busulfan, melphalan and thiotepa were randomized to receive rhIL-11 or placebo daily for 15 days following autologous HPCT. While patients who received rhIL-11 did have other side effects, including infections, sepsis, and veno-occlusive disease, there was a trend towards decreasing severity, incidence and duration of oral mucositis in this group.
Amifostine
Amifostine is an organic thiophosphate prodrug that is dephosphorylated in the tissues to its active metabolite (WR-1065) by membrane-bound alkaline phosphatase. Differences in the alkaline phosphatase concentration of normal vs malignant tissues result in greater activation in normal tissues, 66 resulting in selective cytoprotection. By acting as a potent scavenger of free radicals, amifostine has been shown to protect against the toxicities of both chemotherapy, [67] [68] [69] [70] [71] and radiotherapy [72] [73] [74] [75] in normal cells, without diminishing the effects of therapy on malignant tissues. 66 It was originally approved to ameliorate the renal toxicity associated with cis-platin-based chemotherapy regimens. However, it has been shown in various settings to decrease mucosal toxicity associated with both radiation-and chemotherapy-induced injury. Low doses of amifostine (200 mg/m 2 ), when given within 30 min prior to radiotherapy, can decrease the mucositis which is problematic in patients being treated for cancers of the head and neck. 76 Higher doses (740-910 mg/m 2 ) will decrease toxicity related to high dose chemotherapy. [77] [78] [79] In an ongoing study 77 
Transforming growth factor beta
Transforming Growth Factor Beta 3 (TGF-b3) is one of the family of growth factors, including TGF-b1, TGF-b2, and TGF-b3, which act by arresting or prolonging cell cycling in G1, providing potent negative regulation of epithelial and hematopoietic stem cell growth. 80 In hamsters, both topical and submucosal injections of TGF-b3 have been shown to decrease proliferation of oral mucosal cells. In hamsters treated with 5-fluorouracil, TGF-b3 decreased the severity and duration of mucositis, leading to less weight loss and prolonged survival. Early studies in humans have also shown promising results. In a dose escalation study, 81 11 patients with breast cancer received chemotherapy, with or without stem cell rescue with TGFb3 mouthwashes four times daily for 4 days starting with the first day of chemotherapy. All dose levels (20, 50 and 100 mg/ml) were well tolerated. Further studies are needed to evaluate the efficacy.
Laser therapy
An interesting study, using laser therapy, was conducted in patients who received preparative regimens of total body irradiation (2 Gy BID, days À3 through À1) combined with high-dose cyclophosphamide (60 mg/kg, days À5 and À4) or high-dose melphalan (140 mg/kg, day -4) prior to autologous bone marrow transplant. 82 On days À5 through À1, patients also received helium-neon laser (632.8 nm wavelength, power 60 mW) applications to five sites on the oral mucosa, or sham treatments. Oral assessment was performed through day 20 following transplant. Oral mucositis including time of onset, peak severity and duration were reduced in patients who received laser treatments, as were associated pain, narcotic use, and xerostomia. However, the need for parenteral nutrition was not. Low-energy lasers are known to provide wound healing, presumably by increasing collagen production stimulating fibroblast transformation into myofibroblasts.
Summary
HPCT is based on the concept that dose escalation can eradicate residual microscopic burdens of malignancy. Regimen-related toxicity has been reduced by the acceleration of hematopoietic recovery and shorter durations of neutropenia. In this setting, reducing the incidence and severity of other post-transplant toxicities is the next crucial step to making HPCT safer and/or allowing further dose escalation. The multiplicity of agents tested in the hopes that they might provide protection of the gastrointestinal mucosa attests to the importance of this problem in the transplant community. While no single agent has definitively demonstrated benefit, a number of agents show clinical promise and warrants further trials either as single agents or as combination therapy. Many centers are attempting to adjust current strategies, including the use of mycophenolate mofetil instead of methotrexate for GVHD prophylaxis, the use of decreased doses of total body irradiation and the use of nonmyeloablative transplant regimens. While there may be promise in such endeavors, each has its own risk, including that of graft rejection, relapse or GVHD. Thus, these endeavors are best suited to investigational studies.
Specific recommendations can be made for all patients undergoing HPCT (Table 4 ). These include: pretransplant oral evaluation by a qualified dentist, good routine oral health maintenance during the peritransplant period, use of appropriate analgesics including parenteral narcotics as necessary, active participation in investigational studies of new agents, and maintenance of adequate platelet and neutrophil counts (as far as possible) to improve healing. 
